Skip to content

Clinical study and targeted metabolomics of Yixintong capsule for the treatment of cardiac insufficiency after acute myocardial infarction

Clinical study and targeted metabolomics of Yixintong capsule for the treatment of cardiac insufficiency after acute myocardial infarction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000604
Enrollment
Unknown
Registered
2025-03-27
Start date
2025-03-31
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

Control group:Conventional Western Anti-Heart Failure Therapy
Treatment group:Conventional western medicine combined with Yixintong capsule therapy

Sponsors

Tai'an Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Patients who meet the diagnostic criteria for heart failure after acute myocardial infarction; 2) Patients who meet the diagnostic criteria for traditional Chinese medicine syndromes of Qi deficiency and blood stasis; 3) Age between 40 and 80 years regardless of gender; 4) Left ventricular ejection fraction (LVEF) < 50%; 5) Killip classification I (with left heart failure lung rales affecting < 50% of lung fields) to III (acute pulmonary edema dry rales in the whole lung and large medium and small wet rales); 6) No contraindications to the study medication and willing to sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1) Patients with restrictive cardiomyopathy dilated cardiomyopathy rheumatic heart disease hypertrophic (obstructive) cardiomyopathy uncorrected primary valvular disease myocarditis or malignant arrhythmias; 2) Patients with liver and kidney dysfunction malignant tumors autoimmune diseases or hematological disorders; 3) Patients with cardiogenic shock systolic blood pressure < 100 mmHg or severe infections; 4) Patients with allergies to multiple drugs or those with allergic constitutions; 5) Pregnant or breastfeeding women; 6) Patients who have participated in other clinical trials within the past 2 months or have taken other traditional Chinese medicine decoctions within the past 2 weeks.

Design outcomes

Secondary

MeasureTime frame
LVEDD;LVESD;

Primary

MeasureTime frame
NT-proBNP;Lee's Heart Failure Score;LVEF;6 minutes walking distance;Chinese Medicine Score;MLHFQ Quality of Life Score;

Countries

China

Contacts

Public ContactWei Li

Tai'an Hospital of Traditional Chinese Medicine

liw1013@126.com17662373876

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026